Generic Launched for Vigamox
July 5, 2017 – Lupin has launched a generic for Vigamox® (moxifloxacin ophthalmic solution, 0.5%), manufactured by Novartis. Moxifloxacin is a fluoroquinolone antibiotic used in the eyes to treat conjunctivitis (eye infections) caused by moxifloxacin-susceptible bacteria. IMS reports that Vigamox had sales of $268 million in the U.S. for the 12-month period ending on March 31, 2107.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- U.S. Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.